Jane Street’s Regulus Therapeutics RGLS Stock Holding History

Jane Street’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-29,580	Closed	-$46.4K	–	10376
2024 Q3	$46.4K	Buy	+29,580	New	+$48.9K	﹤0.01%	9192
2023 Q2	–	Sell	-18,189	Closed	-$15.4K	–	9438
2023 Q1	$15.4K	Buy	+18,189	New	+$24.1K	﹤0.01%	8691
2022 Q2	–	Sell	-7,364	Closed	-$22K	–	10675
2022 Q1	$22K	Buy	7,364 +4,921	+201%	+$12.8K	﹤0.01%	9910
2021 Q4	$8K	Buy	+2,443	New	+$10.9K	﹤0.01%	9922
2021 Q3	–	Sell	-5,943	Closed	-$48K	–	10589
2021 Q2	$48K	Buy	5,943 +4,525	+319%	+$50.5K	﹤0.01%	9519
2021 Q1	$22K	Buy	+1,418	New	+$21K	﹤0.01%	8968
2020 Q3	–	Sell	-2,017	Closed	-$14K	–	7792
2020 Q2	$14K	Buy	+2,017	New	+$13.2K	﹤0.01%	6982
2019 Q3	–	Sell	-3,245	Closed	-$41K	–	5641
2019 Q2	$41K	Sell	3,245 -3,066	-49%	-$35.3K	﹤0.01%	4975
2019 Q1	$64K	Buy	+6,311	New	+$68.6K	﹤0.01%	4809

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's RGLS Position: Q4 2024 in Review

Jane Street sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 29,580 shares — an estimated $46.4K sold.

Jane Street first reported a position in RGLS in Q1 2019 and held it in 9 quarters. The position peaked at $64K in Q1 2019. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

Jane Street reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
Jane Street sold 29,580 Regulus Therapeutics shares in Q4 2024, an estimated $46.4K.
Jane Street first reported a position in Regulus Therapeutics in Q1 2019 and held it in 9 quarters.
Jane Street's Regulus Therapeutics position peaked at $64K in Q1 2019.
69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on Jane Street's 13F filing for Q4 2024, filed 14 Feb 2025.